- $1.45bn
- $1.39bn
- $1.11bn
- 87
- 57
- 63
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.96 | ||
| PEG Ratio (f) | 0.3 | ||
| EPS Growth (f) | 132.92% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | 5.54 | ||
| Price to Free Cashflow | 10.75 | ||
| Price to Sales | 1.3 | ||
| EV to EBITDA | 13.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.02% | ||
| Return on Equity | 1.03% | ||
| Operating Margin | 0.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 892.21 | 1,132.02 | 1,295.95 | 1,147.11 | 1,112.24 | 1,131.58 | 1,180.89 | 4.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -38.11 | +103.19 | -75.17 | n/a | n/a | +442.92 | +10.36 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
Directors
- Randall Lipps CHM (63)
- Peter Kuipers CFO (49)
- Christine Mellon CHO
- Daniel Johnston EVP (57)
- Scott Seidelmann EVP (45)
- James Judson LED (66)
- Robin Seim DRC (61)
- Joanne Bauer IND (65)
- Edward Bousa IND
- Vance Moore IND (60)
- Mark Parrish IND (65)
- Bruce Scott IND (65)
- Bruce Smith IND (73)
- Sara White IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 14th, 2000
- Public Since
- August 8th, 2001
- No. of Shareholders
- 74
- No. of Employees
- 3,670
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 46,843,604
- Address
- 4220 NORTH FREEWAY, FORT WORTH, 76137
- Web
- https://www.omnicell.com/
- Phone
- +1 6502516100
- Contact
- Kathleen Nemeth
- Auditors
- Deloitte & Touche LLP
Upcoming Events for OMCL
Q1 2025 Omnicell Inc Earnings Release
Omnicell Inc Annual Shareholders Meeting
Omnicell Inc Annual Shareholders Meeting
Q2 2025 Omnicell Inc Earnings Release
Similar to OMCL
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Omnicell share price?
As of Today at 22:27 UTC, shares in Omnicell are trading at $30.96. This share price information is delayed by 15 minutes.
How has the Omnicell share price performed this year?
Shares in Omnicell last closed at $30.96 and the price had moved by +14.12% over the past 365 days. In terms of relative price strength the Omnicell share price has outperformed the S&P500 Index by +5.33% over the past year.
What are the analyst and broker recommendations for Omnicell?
The overall consensus recommendation for Omnicell is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Omnicell dividend yield?
Omnicell does not currently pay a dividend.
Does Omnicell pay a dividend?
Omnicell does not currently pay a dividend.
When does Omnicell next pay dividends?
Omnicell does not currently pay a dividend.
How do I buy Omnicell shares?
To buy shares in Omnicell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Omnicell?
As of the previous close price of $30.96, shares in Omnicell had a market capitalisation of $1.45bn.
Where are Omnicell shares listed?
Here are the trading details for Omnicell:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OMCL
What kind of share is Omnicell?
Based on an overall assessment of its quality, value and momentum Omnicell is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Omnicell share price forecast for 2025?
The analyst consensus target price for shares in Omnicell is $53.00. That is 71.19% above the last closing price of $30.96.
Analysts covering Omnicell currently have a consensus Earnings Per Share (EPS) forecast of $1.77 for the next financial year.
Find out moreWhat is the trend in the Omnicell share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Omnicell. Over the past six months, its share price has underperformed the S&P500 Index by -17.39%.
As of the last closing price of $30.96, shares in Omnicell were trading -23.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Omnicell PE Ratio?
The Omnicell PE ratio based on its reported earnings over the past 12 months is 16.96. The shares last closed at $30.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Omnicell?
Omnicell's management team is headed by:
- Randall Lipps - CHM
- Peter Kuipers - CFO
- Christine Mellon - CHO
- Daniel Johnston - EVP
- Scott Seidelmann - EVP
- James Judson - LED
- Robin Seim - DRC
- Joanne Bauer - IND
- Edward Bousa - IND
- Vance Moore - IND
- Mark Parrish - IND
- Bruce Scott - IND
- Bruce Smith - IND
- Sara White - IND